



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION IV

PDR

Walnut Creek Field Office
1450 Maria Lane
Walnut Creek, California 94596-5368

June 16, 1994

Department of Veterans Affairs
Medical Center
3801 Miranda Avenue
Palo Alto, California 94304

ATTENTION: JOHN HOLMES, RADIATION SAFETY OFFICER

SUBJECT: Docket Number: 030-20404
 License Number: 04-23242-01
 Plan File Date: 07-MAY-92
 Region Number: 4

Dear Mr. Holmes:

This refers to the review of your written Quality Management Program (QMP) submitted in accordance with 10 CFR 35.32. A review of the QMP was performed to determine whether policies and procedures have been developed to meet the objectives of the rule. Based on this submission, there appear to be significant weaknesses and potential substantial failure of your QMP to meet the objectives in 10 CFR 35.32 in that:

Regarding Brachytherapy

- 1 Your procedures should include a requirement for verification, before administering each brachytherapy dose, that the specific details of the administration are in accordance with the written directive and plan of treatment. The prescribed radioisotope, number of sources, source strengths, treatment site, loading sequence, and total dose should be confirmed by the person administering the brachytherapy treatment to verify agreement with the written directive and treatment plan.

- 2 Your QMP must include a commitment to retain each written directive and a record of each administered radiation dose for three years after the date of administration as required in 10 CFR 35.32(d). Describe the procedure for a qualified individual under the supervision of an authorized user (e.g., an oncology physician, radiation therapy physicist, dosimetrist, or radiation therapy technologist) after administering a dose or dose fraction, to make a written record. Your procedure should describe what this record will include.

200040
9406240007 940616
PDR ADOCK 03020404
C PDR

1/1
1500
1550

Describe the procedure for a qualified individual under the supervision of an authorized user (e.g., an oncology physician, radiation therapy physicist, dosimetrist, or radiation therapy technologist) after administering a dose or dose fraction, to make a written record. Your procedure should describe what this record will include.

- 3 As required in 10 CFR 35.32(c), the licensee shall evaluate and respond, within 30 days after discovery of the recordable event, to each recordable event by: (a) assembling the relevant facts including the cause, (b) identifying what, if any, corrective action is required to prevent recurrence, and (c) retaining a record, in an auditable form, for three years, of the relevant facts and what corrective action was taken. Please include such a provision in your QMP.
- 4 Your QMP should include a procedure to expand the number of cases reviewed when a misadministration or recordable event is uncovered during the periodic review of your QMP. Please include such a provision in your QMP.
- 5 Please provide assurance that modifications to your QMP will be submitted to the NRC within 30 days after the modification has been made as required by 10 CFR 35.32(e).
- 6 Please provide assurance that records of each QMP review and evaluation will be maintained for three years as required in 10 CFR 35.32 (b)(3).
- 7 Please be advised that multiple misadministrations and other errors have occurred due to sources that are inaccurately placed or have moved. In addition, wrong organs have been irradiated as a result of unintentional and undetected movement of the source, once implanted. Each licensee should review their procedures to ensure that source positions are verified and frequently checked.

Regarding I-125 and /or I-131 > 30 microcuries

- 1 A written QMP must be established and maintained for each I-125 and /or I-131 > 30 microcuries use as required in 10 CFR 35.32(f)(1). Please provide your QMP for your NaI I-125 or I-131 >30 microcuries.

Regarding Therapeutic Radiopharmaceutical other than I-125 and/or I-131

- 1 A written QMP must be established and maintained for use of Radio-

pharmaceuticals for therapy other than I-125 and I-131 as required in 10 CFR 35.32(f)(1). Please submit your QMP for your Radio-pharmaceutical therapy.

To meet the requirements in 10 CFR 35.32, you may choose to utilize the procedures described in Regulatory Guide 8.33(enclosed), or submit procedures that are equivalent. If you choose to use Regulatory Guide 8.33, be certain that the procedures you select are adjusted to meet the specific needs of your program as necessary. Additionally, you are reminded that training and/or instruction of supervised individuals in your QMP is required by 10 CFR 35.25.


Due to the apparent failure of your written QMP to meet the objectives in 10 CFR 35.32, you must immediately modify your written QMP to address the items listed above, and provide those modifications to your NRC regional office within 30 days of the date of this letter. NRC will review these matters during your next routine NRC inspection to determine whether violations of NRC requirements have occurred. Enforcement action may be taken at that time for failure to meet the requirements of 10 CFR 35.32.

Please be advised that this QMP will not be incorporated into your license by condition. This allows you the flexibility to make changes to your quality management program without obtaining prior NRC approval. When modifications are made to your program, You should submit any changes to your QMP to this Office within 30 days as required by 10 CFR 35.32(e).

Your QMP was reviewed by an NRC contractor following a standard review plan and related checklist provided by the NRC staff. This letter outlining the findings of that review was prepared by the contractor utilizing standard paragraphs previously reviewed and approved by NRC headquarters and regional management.

Thank you for your cooperation in this matter. If you have any questions, please call me at 510-975-0249.

Sincerely yours,



James L. Montgomery
Senior Materials Specialist
Materials Branch
Region IV, WCFO
Walnut Creek, California 94596

Enclosure: Regulatory Guide 8.33

Department of Veterans Affairs

bcc w/o enclosure:

S. Merchant/NMSS

M. Witte, LLNL

M. Smith, WCFO

Edwin M. Leidholdt, Jr., Ph.D.
Radiation Safety Program Manager
301 Howard Street, Suite 700
San Francisco, CA 94105-2241

Docket File
Inspection File

JMontgomery <i>Jm</i>	SEND TO PDR	SEND TO DCS
REQUEST COPY YES ___ NO <input checked="" type="checkbox"/>	YES <input checked="" type="checkbox"/> NO ___	YES <input checked="" type="checkbox"/> NO ___
6/16/94		